Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.
TUM researchers have found that methylglyoxal underlies MDSC-mediated immunosuppression with implications for cancer diagnosis and treatment.
Interim analysis of the ZUMA-5 trial found that Yescarta showed efficacy for treating relapsed or refractory indolent non-hodgkin lymphoma.
Disulfiram, a drug approved by the FDA for treating alcohol addiction, has been found to antagonize inflammation and could treat key diseases .
Research by Dr. Arne Akbar and colleagues has shown that NK cell-like behavior of aging CD8+ T cells is linked to the expression of sestrins.
T-COVID is anticipated to provide clinical benefit to COVID-19 patients that are not yet hospitalized in the phase 1/2 clinical trial.
Novavax has purchased Praha Vaccines, a biologics manufacturer in the Czech Republic, to support mass production of its COVID-19 vaccine.